ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
Clinical outcomes of cryptogenic new onset refractory status epilepticus (NORSE) in a tertiary hospital in Singapore: a case series.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNew Onset Refractory Status Epilepticus (NORSE) is a neurological emergency with high mortality. Cryptogenic NORSE (cNORSE) is defined by a lack of an identifiable structural, toxic or metabolic etiology despite extensive workup. Survivors often develop significant long-term neurological sequelae and drug-resistant epilepsy. However, studies have shown that despite prolonged hospitalization, a significant proportion of cNORSE patients can achieve favourable functional outcomes.
methodsA retrospective review of adult cNORSE patients between July 2019 and July 2023 in a tertiary hospital in Singapore was performed.
resultsThirteen patients with cNORSE were identified. Median age at presentation was 32.2 [IQR: 23.9-44.1] years and 6 (46.2%) of the patients were male. Eight (61.5%) patients fulfilled criteria for Febrile Infection-Related Epilepsy Syndrome (FIRES). Eight (61.5%) patients had abnormal index brain MRIs. The median duration of ICU stay was 37.0 [22.8-41.5] days. The total number of anti-seizure medications (ASMs) and anesthetics used was 6 [5-7] and 3 [2-4] respectively. All patients received immunotherapy and the time to immunotherapy initiation from SE onset was 2 [1-3] days. 4 (30.8%) patients demised during inpatient stay. Of 9 surviving patients, the median MRS on discharge was 4 [3-5]. MRS at 3 month and 1 year follow ups was 2 [1-5] and 1.0 [0.8-5.0] respectively.
conclusionsThis retrospective study characterizes a cryptogenic NORSE cohort in a tertiary hospital in Singapore. Cryptogenic NORSE is associated with significant morbidity and mortality; however, long term outcomes may still be favourable in patients with initially severe illness and protracted ICU stay.
Indexed as
Identifiers
40053179What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.